NEMLUVIO (Galderma Australia Pty Ltd)
Product name
NEMLUVIO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
200 (255 working days)
Active ingredients
nemolizumab
Registration type
NCE/ NBE
Indication
Atopic Dermatitis
Nemluvio is indicated for the treatment of moderate-to-severe atopic dermatitis (AD) in combination with topical corticosteroids and/ or topical calcineurin inhibitors in adults and patients aged 12 years and above who weigh at least 30 kg, who are candidates for systemic therapy.
Prurigo Nodularis
Nemluvio is indicated for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.